Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Hepatology. 2010 Oct;52(4):1291-300. doi: 10.1002/hep.23837.
Interleukin-22 (IL-22), a recently identified member of the IL-10 family of cytokines that is produced by Th17 and natural killer cells, plays an important role in controlling bacterial infection, homeostasis, and tissue repair. Here, we tested the effect of IL-22 on alcohol-induced liver injury in a murine model of chronic-binge ethanol feeding. Feeding male C57BL/6 mice with a Lieber-DeCarli diet containing 5% ethanol for 10 days, followed by a single dose of ethanol (5 g/kg body weight) by gavage, induces significant fatty liver and liver injury with peak serum levels of approximately 250 IU/L alanine aminotransferase and 420 IU/L aspartate aminotransferase 9 hours after gavage. Moreover, chronic-binge ethanol administration increases expression of hepatic and serum inflammatory cytokines and hepatic oxidative stress. Using this model, we demonstrate that treatment with IL-22 recombinant protein activates hepatic signal transducer and activator of transcription 3 (STAT3) and ameliorates alcoholic fatty liver, liver injury, and hepatic oxidative stress. Administration with IL-22 adenovirus also prevents alcohol-induced steatosis and liver injury. Deletion of STAT3 in hepatocytes abolishes the hepatoprotection provided by IL-22 in alcoholic liver injury. In addition, IL-22 treatment down-regulates the hepatic expression of fatty acid transport protein, but up-regulates several antioxidant, antiapoptotic, and antimicrobial genes. Finally, expression of IL-22 receptor 1 is up-regulated whereas IL-22 is undetectable in the livers from mice with chronic-binge ethanol feeding or patients with alcoholic hepatitis.
Chronic-binge ethanol feeding may be a useful model to study the early stages of alcoholic liver injury. IL-22 treatment could be a potential therapeutic option to ameliorate alcoholic liver disease, due to its antioxidant, antiapoptotic, antisteatotic, proliferative, and antimicrobial effects with the added benefit of potentially few side effects.
白细胞介素-22(IL-22)是白细胞介素-10 家族中的一种新发现的细胞因子,由 Th17 和自然杀伤细胞产生,在控制细菌感染、体内平衡和组织修复方面发挥着重要作用。在这里,我们在慢性 binge 乙醇喂养的小鼠模型中测试了 IL-22 对酒精性肝损伤的影响。用含有 5%乙醇的 Lieber-DeCarli 饮食喂养雄性 C57BL/6 小鼠 10 天,然后通过灌胃给予单剂量乙醇(5g/kg 体重),可诱导显著的脂肪肝和肝损伤,灌胃后 9 小时血清丙氨酸氨基转移酶峰值约为 250IU/L,天冬氨酸氨基转移酶峰值约为 420IU/L。此外,慢性 binge 乙醇给药增加了肝和血清炎症细胞因子的表达和肝氧化应激。使用该模型,我们证明 IL-22 重组蛋白治疗激活了肝信号转导和转录激活因子 3(STAT3),并改善了酒精性脂肪肝、肝损伤和肝氧化应激。IL-22 腺病毒给药也可预防酒精性脂肪变性和肝损伤。肝细胞中 STAT3 的缺失消除了 IL-22 在酒精性肝损伤中的肝保护作用。此外,IL-22 治疗下调了脂肪酸转运蛋白的肝表达,但上调了几种抗氧化、抗凋亡和抗微生物基因。最后,在慢性 binge 乙醇喂养的小鼠或酒精性肝炎患者的肝脏中,IL-22 受体 1 的表达上调,而 IL-22 检测不到。
慢性 binge 乙醇喂养可能是研究酒精性肝损伤早期阶段的有用模型。由于 IL-22 具有抗氧化、抗凋亡、抗脂肪变性、增殖和抗菌作用,并且可能具有较少的副作用,因此治疗可能是改善酒精性肝病的一种潜在治疗选择。